Le cluster Tomography, X-Ray Computed - Prostatic Neoplasms (radiotherapy)

Terms

3	Tomography, X-Ray Computed
3	Prostatic Neoplasms (radiotherapy)
2	Prostatic Neoplasms (surgery)
2	Prostatic Neoplasms (blood)
2	Prostatectomy

Associations

Freq.	Weight	Association
2	2	Prostatic Neoplasms (radiotherapy) - Tomography, X-Ray Computed
2	2	Prostatic Neoplasms (radiotherapy) - Prostatic Neoplasms (surgery)
2	2	Prostatic Neoplasms (blood) - Prostatic Neoplasms (surgery)
2	2	Prostatic Neoplasms (blood) - Prostatic Neoplasms (radiotherapy)
2	2	Prostatectomy - Prostatic Neoplasms (surgery)
2	2	Prostatectomy - Prostatic Neoplasms (radiotherapy)
2	2	Prostatectomy - Prostatic Neoplasms (blood)

Documents par ordre de pertinence

000045 (2005)	John F Ward (États-Unis) ; Judd W Moul	Biochemical recurrence after definitive prostate cancer therapy. Part I: defining and localizing biochemical recurrence of prostate cancer.
000032 (2008)	Bridget F Koontz (États-Unis) ; Vladimir Mouraviev ; Jeffrey L Johnson ; Janice Mayes ; Stephanie H Chen ; Terence Z Wong ; Mitchell S Anscher ; Leon Sun ; Judd Moul ; Thomas J Polascik	Use of local (111)in-capromab pendetide scan results to predict outcome after salvage radiotherapy for prostate cancer.
000046 (2004)	Rodney J Ellis (États-Unis) ; Edward Kim ; Ryan Foor	Role of ProstaScint for brachytherapy in localized prostate adenocarcinoma.
000067 (1998)	P J Bohdiewicz (États-Unis)	Indium-111 satumomab pendetide: the first FDA-approved monoclonal antibody for tumor imaging.

Wicri

This area was generated with Dilib version V0.5.76.
Data generation: Tue May 20 07:24:43 2014. Site generation: Tue May 20 08:20:52 2014